[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Identifieur interne : 003053 ( Main/Exploration ); précédent : 003052; suivant : 003054[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Auteurs : N V FedorovaSource :
- Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [ 1997-7298 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Piribedil (administration & dosage), Piribedil (adverse effects), Piribedil (therapeutic use), Placebos, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Piribedil.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- drug therapy : Parkinson Disease.
- Drug Therapy, Combination, Humans, Placebos, Time Factors, Treatment Outcome.
Abstract
The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.
PubMed: 14681961
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001146
- to stream PubMed, to step Curation: 001105
- to stream PubMed, to step Checkpoint: 001105
- to stream Ncbi, to step Merge: 000406
- to stream Ncbi, to step Curation: 000406
- to stream Ncbi, to step Checkpoint: 000406
- to stream Main, to step Merge: 003486
- to stream Main, to step Curation: 003053
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title><author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14681961</idno><idno type="pmid">14681961</idno><idno type="wicri:Area/PubMed/Corpus">001146</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001146</idno><idno type="wicri:Area/PubMed/Curation">001105</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001105</idno><idno type="wicri:Area/PubMed/Checkpoint">001105</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001105</idno><idno type="wicri:Area/Ncbi/Merge">000406</idno><idno type="wicri:Area/Ncbi/Curation">000406</idno><idno type="wicri:Area/Ncbi/Checkpoint">000406</idno><idno type="wicri:doubleKey">1997-7298:2003:Fedorova N:use:of:pronoran</idno><idno type="wicri:Area/Main/Merge">003486</idno><idno type="wicri:Area/Main/Curation">003053</idno><idno type="wicri:Area/Main/Exploration">003053</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title><author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name></author></analytic><series><title level="j">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</title><idno type="ISSN">1997-7298</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Piribedil (administration & dosage)</term><term>Piribedil (adverse effects)</term><term>Piribedil (therapeutic use)</term><term>Placebos</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Humans</term><term>Placebos</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003053 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003053 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:14681961
|texte= [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14681961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |